Lenalidomide Modulates IL-8 and Anti-Prostate Antibody Levels in Men with Biochemically Recurrent Prostate Cancer

BACKGROUND: We retrospectively explored changes in immunological parameters in men with biochemically recurrent prostate cancer treated with either 5mg or 25mg of lenalidomide in a randomized phase 2 trial, and determined whether those changes correlated with disease progression. METHODS: Cytokine l...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Zabransky, Daniel J., Smith, Heath A., Thoburn, Christopher J., Zahurak, Marianna, Keizman, Daniel, Carducci, Michael, Eisenberger, Mario A., McNeel, Douglas G., Drake, Charles G., Antonarakis, Emmanuel S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3248613/
https://ncbi.nlm.nih.gov/pubmed/21748755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.21449
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller